JP2006514095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514095A5 JP2006514095A5 JP2004570721A JP2004570721A JP2006514095A5 JP 2006514095 A5 JP2006514095 A5 JP 2006514095A5 JP 2004570721 A JP2004570721 A JP 2004570721A JP 2004570721 A JP2004570721 A JP 2004570721A JP 2006514095 A5 JP2006514095 A5 JP 2006514095A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- optionally substituted
- hydroxy
- halogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 14
- -1 amino, carbamoylamino Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000004423 acyloxy group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 5
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 5
- 230000036407 pain Effects 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000001589 carboacyl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- JXPBXIHMWWCJOP-UHFFFAOYSA-N 2-[4-[5-(difluoromethyl)-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]phenoxy]ethylurea Chemical compound C1=NC(OC)=CC=C1N1C(C=2C=CC(OCCNC(N)=O)=CC=2)=CC(C(F)F)=N1 JXPBXIHMWWCJOP-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000027932 Collagen disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000000676 alkoxyimino group Chemical group 0.000 claims 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 2
- FPXNNUNEGDQEEC-UHFFFAOYSA-N 2-[4-[2-(4-methoxyphenyl)-5-(trifluoromethyl)pyrazol-3-yl]phenoxy]ethylurea Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OCCNC(N)=O)=CC=2)=CC(C(F)(F)F)=N1 FPXNNUNEGDQEEC-UHFFFAOYSA-N 0.000 claims 1
- FDRDFEKIGYWPSC-UHFFFAOYSA-N 2-[4-[5-(2,2-difluoroethoxy)-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]phenoxy]ethylurea Chemical compound C1=NC(OC)=CC=C1N1C(C=2C=CC(OCCNC(N)=O)=CC=2)=CC(OCC(F)F)=N1 FDRDFEKIGYWPSC-UHFFFAOYSA-N 0.000 claims 1
- QLAJUMUUDDMEHU-UHFFFAOYSA-N 2-[4-[5-(difluoromethyl)-2-(4-methoxyphenyl)pyrazol-3-yl]phenoxy]ethylurea Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OCCNC(N)=O)=CC=2)=CC(C(F)F)=N1 QLAJUMUUDDMEHU-UHFFFAOYSA-N 0.000 claims 1
- UUGMIZDHEMPULY-UHFFFAOYSA-N 2-[4-[5-chloro-2-(4-methoxyphenyl)pyrazol-3-yl]phenoxy]ethylurea Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OCCNC(N)=O)=CC=2)=CC(Cl)=N1 UUGMIZDHEMPULY-UHFFFAOYSA-N 0.000 claims 1
- LENXFAWECVJUBW-UHFFFAOYSA-N 2-[4-[5-cyclopropyl-2-(4-methoxyphenyl)pyrazol-3-yl]phenoxy]ethylurea Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OCCNC(N)=O)=CC=2)=CC(C2CC2)=N1 LENXFAWECVJUBW-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- FPMLBLDBMKTMDQ-UHFFFAOYSA-N [4-[5-(difluoromethyl)-2-(4-methoxyphenyl)pyrazol-3-yl]phenyl]methylurea Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(CNC(N)=O)=CC=2)=CC(C(F)F)=N1 FPMLBLDBMKTMDQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Chemical group 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZKXOUIFLUUCMSW-UHFFFAOYSA-N n-[2-[4-[2-(4-methoxyphenyl)-5-(trifluoromethyl)pyrazol-3-yl]phenoxy]ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(OCCNC(C)=O)=CC=2)=CC(C(F)(F)F)=N1 ZKXOUIFLUUCMSW-UHFFFAOYSA-N 0.000 claims 1
- QPXJUXYRSPPCMP-UHFFFAOYSA-N n-[[4-[5-(difluoromethyl)-2-(4-methoxyphenyl)pyrazol-3-yl]phenyl]methyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(CNS(C)(=O)=O)=CC=2)=CC(C(F)F)=N1 QPXJUXYRSPPCMP-UHFFFAOYSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 0 ***c(cc1)ccc1C(C(*)C(*)=O)=O Chemical compound ***c(cc1)ccc1C(C(*)C(*)=O)=O 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002953019A AU2002953019A0 (en) | 2002-12-02 | 2002-12-02 | Azole derivatives |
| AU2002953602A AU2002953602A0 (en) | 2002-12-30 | 2002-12-30 | New compounds |
| AU2003902015A AU2003902015A0 (en) | 2003-04-29 | 2003-04-29 | Azole derivatives |
| PCT/JP2003/014489 WO2004050632A1 (en) | 2002-12-02 | 2003-11-14 | Pyrazole derivatives useful as cox-i inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514095A JP2006514095A (ja) | 2006-04-27 |
| JP2006514095A5 true JP2006514095A5 (https=) | 2006-06-15 |
| JP4419078B2 JP4419078B2 (ja) | 2010-02-24 |
Family
ID=32474716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004570721A Expired - Fee Related JP4419078B2 (ja) | 2002-12-02 | 2003-11-14 | ピラゾール誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7183306B2 (https=) |
| EP (1) | EP1567503B1 (https=) |
| JP (1) | JP4419078B2 (https=) |
| KR (1) | KR20050083761A (https=) |
| AR (1) | AR042273A1 (https=) |
| AT (1) | ATE538097T1 (https=) |
| BR (1) | BR0316332A (https=) |
| CA (1) | CA2505945A1 (https=) |
| ES (1) | ES2379076T3 (https=) |
| MX (1) | MXPA05005742A (https=) |
| NO (1) | NO20053215L (https=) |
| NZ (1) | NZ540515A (https=) |
| PL (1) | PL377778A1 (https=) |
| TW (1) | TW200410942A (https=) |
| WO (1) | WO2004050632A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002055502A1 (en) * | 2001-01-02 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine derivatives useful as cyclooxygenase inhibitor |
| KR20050083761A (ko) | 2002-12-02 | 2005-08-26 | 후지사와 야꾸힝 고교 가부시키가이샤 | Ｃｏｘ－ｉ저해제로서 유용한 피라졸 유도체 |
| KR20050096956A (ko) | 2003-02-07 | 2005-10-06 | 다이이찌 세이야꾸 가부시기가이샤 | 피라졸 유도체 |
| US20050075323A1 (en) * | 2003-03-05 | 2005-04-07 | Pfizer Inc | Beta3 adrenergic receptor agonists and uses thereof |
| US20060079566A1 (en) * | 2003-10-03 | 2006-04-13 | Ching-Shih Chen | PDK-1/Akt signaling inhibitors |
| ATE440085T1 (de) * | 2004-02-20 | 2009-09-15 | Astrazeneca Ab | 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen |
| US20080064682A1 (en) * | 2004-07-01 | 2008-03-13 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole Derivatives |
| WO2006013962A1 (ja) * | 2004-08-06 | 2006-02-09 | Daiichi Pharmaceutical Co., Ltd. | 抗血小板薬およびその製造方法 |
| EP2368881A1 (en) * | 2005-01-10 | 2011-09-28 | University of Connecticut | Heteropyrazole analogs acting on cannabinoid receptors |
| FR2882365B1 (fr) * | 2005-02-21 | 2007-09-07 | Sanofi Aventis Sa | Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique |
| GB0514739D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
| GB0516661D0 (en) * | 2005-08-13 | 2005-09-21 | Astrazeneca Ab | Therapeutic agents |
| JPWO2007111323A1 (ja) | 2006-03-27 | 2009-08-13 | 東レ株式会社 | ウレイド誘導体およびその医薬用途 |
| EP2070908A4 (en) | 2006-09-07 | 2011-08-10 | Univ Okayama Nat Univ Corp | COMPOUND WITH BENZAMIDE KELET AND CYCLOOXYGENASE (COX-1) -ELECTIVE HEMORATIVE EFFECT |
| EP2121659B1 (en) * | 2006-12-18 | 2013-05-15 | 7TM Pharma A/S | Modulators of cb1 receptors |
| GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
| WO2008105383A1 (ja) * | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
| WO2008114859A1 (ja) * | 2007-03-22 | 2008-09-25 | Astellas Pharma Inc. | ピラゾール誘導体を含有する医薬組成物 |
| US8039502B2 (en) | 2007-07-24 | 2011-10-18 | The Ohio State University Research Foundation | Anti-infective agents against intracellular pathogens |
| JP5704925B2 (ja) | 2008-02-08 | 2015-04-22 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−カンナビノイドコンジュゲート |
| DE102008015032A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| EP2356100A1 (en) * | 2008-10-02 | 2011-08-17 | Cambrex Karlskoga AB | New process for preparing diketones and medicaments |
| TWI435874B (zh) | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
| DE102008062863A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung |
| DE102008062878A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte Furancarboxamide und ihre Verwendung |
| US20120108823A1 (en) | 2009-04-22 | 2012-05-03 | The Ohio State University Research Foundation | Anti-francisella agents |
| DE102009036604A1 (de) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung |
| DE102011055815A1 (de) * | 2011-11-29 | 2013-05-29 | Aicuris Gmbh & Co. Kg | Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung |
| DE102012016908A1 (de) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| KR102498741B1 (ko) | 2016-04-29 | 2023-02-10 | 에프지에이치 바이오테크 인코포레이티드 | 질환 치료용 이-치환된 피라졸 화합물 |
| MX2019001813A (es) | 2016-08-15 | 2019-05-20 | Bayer Cropscience Ag | Procedimiento para la preparacion de pyrazoles de 3-amino-1-(2,6-disustituido-fenilo). |
| JP7071981B2 (ja) * | 2016-09-07 | 2022-05-19 | エフジーエイチ バイオテック，インコーポレーテッド | 疾患の治療のための二置換ピラゾール化合物 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN115611790A (zh) * | 2022-10-31 | 2023-01-17 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种甲硫基甲基苯基醚的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164381A (en) | 1986-05-29 | 1992-11-17 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same |
| US4826868A (en) | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US5051518A (en) | 1987-05-29 | 1991-09-24 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides |
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| US5550147A (en) | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| US5298521A (en) | 1993-08-30 | 1994-03-29 | Ortho Pharmaceutical Corporation | 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use |
| WO1996014302A1 (en) | 1994-11-08 | 1996-05-17 | Eisai Co., Ltd. | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects |
| ES2136018B1 (es) | 1997-06-17 | 2000-07-01 | Menarini Lab | Compuestos inhibidores selectivos de la ciclooxigenasa-i y su utilizacion como analgesicos, antiinflamatorios y antiartriticos. |
| CA2332957A1 (en) | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| WO2000018741A2 (en) * | 1998-09-30 | 2000-04-06 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds as cox-2 inhibitors |
| AU4308300A (en) | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| DE60006057T2 (de) * | 1999-12-03 | 2004-05-27 | Pfizer Products Inc., Groton | Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| AU2001255600A1 (en) * | 2000-04-25 | 2001-11-07 | Pharmacia Corporation | Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| WO2002055502A1 (en) | 2001-01-02 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine derivatives useful as cyclooxygenase inhibitor |
| AUPR878201A0 (en) | 2001-11-09 | 2001-12-06 | Fujisawa Pharmaceutical Co., Ltd. | New compounds |
| US20030162824A1 (en) | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| EP1492773B1 (en) | 2002-04-05 | 2009-02-04 | Cadila Healthcare Ltd. | 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |
| KR20050083761A (ko) | 2002-12-02 | 2005-08-26 | 후지사와 야꾸힝 고교 가부시키가이샤 | Ｃｏｘ－ｉ저해제로서 유용한 피라졸 유도체 |
| CN100421632C (zh) | 2005-02-01 | 2008-10-01 | 金磊 | 人工心脏瓣膜成形环 |
-
2003
- 2003-11-14 KR KR1020057006436A patent/KR20050083761A/ko not_active Abandoned
- 2003-11-14 AT AT03812289T patent/ATE538097T1/de active
- 2003-11-14 MX MXPA05005742A patent/MXPA05005742A/es active IP Right Grant
- 2003-11-14 BR BR0316332-6A patent/BR0316332A/pt not_active IP Right Cessation
- 2003-11-14 CA CA002505945A patent/CA2505945A1/en not_active Abandoned
- 2003-11-14 EP EP03812289A patent/EP1567503B1/en not_active Expired - Lifetime
- 2003-11-14 NZ NZ540515A patent/NZ540515A/en unknown
- 2003-11-14 JP JP2004570721A patent/JP4419078B2/ja not_active Expired - Fee Related
- 2003-11-14 ES ES03812289T patent/ES2379076T3/es not_active Expired - Lifetime
- 2003-11-14 PL PL377778A patent/PL377778A1/pl unknown
- 2003-11-14 US US10/706,999 patent/US7183306B2/en not_active Expired - Fee Related
- 2003-11-14 WO PCT/JP2003/014489 patent/WO2004050632A1/en not_active Ceased
- 2003-12-01 TW TW092133632A patent/TW200410942A/zh unknown
- 2003-12-02 AR ARP030104441A patent/AR042273A1/es unknown
-
2005
- 2005-06-30 NO NO20053215A patent/NO20053215L/no not_active Application Discontinuation
-
2006
- 2006-12-13 US US11/610,230 patent/US20070112037A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514095A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| JP2004512328A5 (https=) | ||
| RU2006116885A (ru) | Производные n-фенил(пиперидин-2-ил)метил-бензамида, способ получения указанных соединений и их применение в терапии | |
| JP7366002B2 (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
| JP2007508361A5 (https=) | ||
| RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
| JP2002501025A5 (https=) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| JP2002520316A5 (https=) | ||
| JP2011500673A5 (https=) | ||
| RU2008115539A (ru) | Производные гидразона и их применение | |
| JP2009540014A (ja) | 胃障害を処置または予防するためのテガセロドを単独でまたはプロトンポンプ阻害剤と組合せて含む組成物 | |
| JP2003521516A (ja) | 胃運動刺激剤としてのｃｏｘ−２阻害剤の使用 | |
| JP2006511446A5 (https=) | ||
| JP2005508872A5 (https=) | ||
| JP2010522218A5 (https=) | ||
| JP2023062064A5 (https=) | ||
| JP2004525184A5 (https=) | ||
| JP2003521511A (ja) | 便秘のためのｃｏｘ−２阻害剤の使用 | |
| JP2007505105A5 (https=) | ||
| JP2009532434A5 (https=) | ||
| RU2000100362A (ru) | Применение специфического антагониста 5нт2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors |